Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Clearbridge Health Ltd. ( (SG:1H3) ) has provided an update.
Clearbridge Health Limited has announced that its binding term sheet for the proposed acquisition of Elpis Biopharmaceuticals Pte. Ltd. has lapsed as of 23 January 2026, after reaching the agreed long-stop date. The company stated that the lapse of the term sheet will not have any material impact on its net tangible assets or earnings per share for the financial year ending 31 December 2026, suggesting limited immediate financial or operational consequences for shareholders and stakeholders.
The most recent analyst rating on (SG:1H3) stock is a Sell with a S$0.01 price target. To see the full list of analyst forecasts on Clearbridge Health Ltd. stock, see the SG:1H3 Stock Forecast page.
More about Clearbridge Health Ltd.
Clearbridge Health Limited is a Singapore-incorporated healthcare company operating in the medical and life sciences sector, with a focus on healthcare-related investments and services in the region.
Technical Sentiment Signal: Sell
Current Market Cap: S$8.59M
For detailed information about 1H3 stock, go to TipRanks’ Stock Analysis page.